IP Library Granted Patent US 10,183,095
Granted Patent B2
US 10,183,095 · App. 14/921,826 · Granted Jan 22, 2019

Treatment of skeletal voids with implantable substrate hydrated with bone marrow concentrate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,183,095
App. No.
14/921,826
Granted
Jan 22, 2019
Kind
B2
Abstract

The invention is directed to a bone void filler comprising a scaffold or matrix. The scaffold or matrix may include a porous inorganic matrix component. The bone void filler may include a cellular component containing cells, some of which are capable of making extracellular matrix resembling native bone tissue. The bone void filler may include an organic matrix, such as, an organic biopolymer that aids in cell retention and renders the scaffold or matrix moldable. The bone void filler may include growth factors and/or cytokines. The bone void filler may include a clotting agent.

Claims (21)

1. A filler combining both autologous and synthetic materials for repair or regeneration of bone tissue, said filler comprising:

a synthetic scaffold matrix comprised of at least one porous granule, the at least one porous granule having a porosity of between either about 50% and about 95% by volume or between about 3% and about 15% by volume, wherein each porous granule of the at least one porous granule is formed from a composition selected from the group consisting of: mono calcium phosphate, tetra calcium phosphate, octacalcium phosphate, carbonate apatite, fluoro apatite;

an autologous cellular component; and

an organic biopolymer, the organic biopolymer comprising at least one of gelatin, alginate, and chitosan.

2. The filler of claim 1 , further comprising a growth factor.

3. The filler of claim 2 , wherein the growth factor comprises at least one of vascular endothelial growth factor and platelet-derived growth factor.

4. The filler of claim 2 , wherein the growth factor is an autologous growth factor that has been concentrated from a biological fluid.

5. The filler of claim 4 , wherein the biological fluid comprises at least one of a platelet poor fraction of blood and bone marrow.

6. The filler of claim 2 , further comprising a synthetically derived cytokine.

7. The filler of claim 2 , wherein the growth factor is a synthetically derived growth factor.

8. The filler of claim 1 , wherein the autologous cellular component comprises autologous bone marrow.

9. The filler of claim 8 , wherein the autologous bone marrow is filtered to remove at least one of red blood cells and extracellular components.

10. The filler of claim 1 , wherein the autologous cellular component comprises autologous adipose tissue.

11. The filler of claim 10 , wherein the autologous adipose tissue comprises progenitor cells.

12. The filler of claim 1 , wherein the autologous cellular component comprises concentrated autologous progenitor cells.

13. The filler of claim 1 , further comprising a clotting agent.

14. The filler of claim 1 , wherein each porous granule of the at least one porous granule further comprises one or more of silicon and strontium.

15. A filler combining both autologous and synthetic materials for repair or regeneration of bone tissue, said filler comprising:

a synthetic scaffold matrix comprised of at least one porous granule, the at least one porous granule having a porosity of between either about 3% and about 15% by volume or between about 50% and about 90% by volume, wherein each porous granule of the at least one porous granule comprises one or more of silicon or strontium;

an autologous cellular component; and

an organic biopolymer, the organic biopolymer comprising at least one of gelatin, alginate, and chitosan.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 10, 2019
From: AMERICAN BANK
To: SPINESMITH HOLIDNGS, LLC
Reel/Frame 048853/0105 →
SECURITY INTEREST Recorded Apr 9, 2019
From: SPINESMITH HOLDINGS, LLC
To: BLUEARC MEZZANINE PARTNERS I, LP
Reel/Frame 048839/0655 →
SECURITY INTEREST Recorded Dec 14, 2017
From: SPINESMITH HOLDINGS, LLC
To: AMERICAN BANK, N.A.
Reel/Frame 044882/0096 →
SECURITY INTEREST Recorded Mar 22, 2017
From: SPINESMITH HOLDINGS, LLC
To: BLUEARC MEZZANINE PARTNERS I, L.P.
Reel/Frame 042071/0370 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2015
From: DAWSON, EILEEN; DUNWORTH, KEVIN; SAND, THEODORE; MURPHY, MATTHEW; ROSSMAN, JOHN B.; SAMANO, MELISSA; SUZUKI, RICHARD; MONCIVAIS, KATY
To: SPINESMITH PARTNERS, L.P.
Reel/Frame 036959/0194 →